Sargent Investment Group LLC trimmed its holdings in Cytosorbents Corporation (NASDAQ:CTSO - Free Report) by 34.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 823,500 shares of the medical research company's stock after selling 425,363 shares during the quarter. Sargent Investment Group LLC owned approximately 1.32% of Cytosorbents worth $824,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in CTSO. Millennium Management LLC bought a new stake in Cytosorbents in the fourth quarter worth $30,000. Key Client Fiduciary Advisors LLC boosted its position in Cytosorbents by 127.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock valued at $78,000 after purchasing an additional 43,900 shares in the last quarter. Renaissance Technologies LLC boosted its position in Cytosorbents by 10.6% during the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock valued at $80,000 after purchasing an additional 8,400 shares in the last quarter. Northern Trust Corp boosted its holdings in Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after acquiring an additional 16,701 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Cytosorbents in the fourth quarter worth about $99,000. 32.87% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of analysts have recently commented on the company. D. Boral Capital restated a "buy" rating and issued a $10.00 price objective on shares of Cytosorbents in a research report on Wednesday, June 25th. Wall Street Zen initiated coverage on Cytosorbents in a research note on Wednesday, May 21st. They issued a "hold" rating on the stock. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $1.00 price target on shares of Cytosorbents in a research note on Thursday, May 15th.
Check Out Our Latest Stock Analysis on Cytosorbents
Cytosorbents Stock Performance
Cytosorbents stock opened at $1.03 on Friday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.30 and a current ratio of 2.61. The stock has a fifty day moving average of $1.03 and a two-hundred day moving average of $1.03. The company has a market capitalization of $64.49 million, a price-to-earnings ratio of -3.68 and a beta of 1.19. Cytosorbents Corporation has a fifty-two week low of $0.71 and a fifty-two week high of $1.61.
Cytosorbents (NASDAQ:CTSO - Get Free Report) last issued its earnings results on Wednesday, May 14th. The medical research company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. Cytosorbents had a negative return on equity of 105.04% and a negative net margin of 41.77%. The firm had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.01 million. On average, analysts anticipate that Cytosorbents Corporation will post -0.3 EPS for the current fiscal year.
Cytosorbents Profile
(
Free Report)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
Featured Stories
Want to see what other hedge funds are holding CTSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytosorbents Corporation (NASDAQ:CTSO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cytosorbents, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytosorbents wasn't on the list.
While Cytosorbents currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
